Le and Loomba reported higher values of indices of liver dysfunction in patients with NAFLD [25], but Kusunoki et al. showed that increases in AST and ALT activities could be reversed by treatment with a lipoprotein lipase-activating agent (NO-1886) that ameliorates fatty liver in a rat model of diabetes and fatty liver [26]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.